Open-Label Extension Study of 23 mg Donepezil SR in Participants With Moderate to Severe Alzheimer's Disease

Completed · Phase 3

Conditions studied: Alzheimer's Disease

In brief

The purpose of this study is to evaluate the safety and efficacy of long-term administration of 23 milligram (mg) donepezil sustained release (SR) in participants with moderate to severe Alzheimer's disease. Participants who complete study E2020-G000-326 (NCT00478205) with no ongoing serious adverse events (SAEs) and no serious adverse drug reactions will be eligible to enter the open-label extension study.

Key facts

Study ID

NCT00566501

Run by

Eisai Inc.

People needed

915

Starts

2007-12-14

Expected to finish

2010-04-01

Last updated by the study team

2021-11-17

Who can join

Age: 45 and older, up to 91. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Apex Research Institute — Santa Ana, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.